These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

355 related items for PubMed ID: 33030583

  • 1. Targeting MALAT1 induces DNA damage and sensitize non-small cell lung cancer cells to cisplatin by repressing BRCA1.
    Huang J, Lin C, Dong H, Piao Z, Jin C, Han H, Jin D.
    Cancer Chemother Pharmacol; 2020 Nov; 86(5):663-672. PubMed ID: 33030583
    [Abstract] [Full Text] [Related]

  • 2. LncRNA MALAT1 Depressed Chemo-Sensitivity of NSCLC Cells through Directly Functioning on miR-197-3p/p120 Catenin Axis.
    Yang T, Li H, Chen T, Ren H, Shi P, Chen M.
    Mol Cells; 2019 Mar 31; 42(3):270-283. PubMed ID: 30841025
    [Abstract] [Full Text] [Related]

  • 3. SNHG14 silencing suppresses the progression and promotes cisplatin sensitivity in non-small cell lung cancer.
    Jiao P, Hou J, Yao M, Wu J, Ren G.
    Biomed Pharmacother; 2019 Sep 31; 117():109164. PubMed ID: 31252267
    [Abstract] [Full Text] [Related]

  • 4. LncRNA MALAT1 promotes migration and invasion of non-small-cell lung cancer by targeting miR-206 and activating Akt/mTOR signaling.
    Tang Y, Xiao G, Chen Y, Deng Y.
    Anticancer Drugs; 2018 Sep 31; 29(8):725-735. PubMed ID: 29916897
    [Abstract] [Full Text] [Related]

  • 5. The PVT1/miR-216b/Beclin-1 regulates cisplatin sensitivity of NSCLC cells via modulating autophagy and apoptosis.
    Chen L, Han X, Hu Z, Chen L.
    Cancer Chemother Pharmacol; 2019 May 31; 83(5):921-931. PubMed ID: 30859368
    [Abstract] [Full Text] [Related]

  • 6. NEAT1 upregulates EGCG-induced CTR1 to enhance cisplatin sensitivity in lung cancer cells.
    Jiang P, Wu X, Wang X, Huang W, Feng Q.
    Oncotarget; 2016 Jul 12; 7(28):43337-43351. PubMed ID: 27270317
    [Abstract] [Full Text] [Related]

  • 7. LncRNA TATDN1 contributes to the cisplatin resistance of non-small cell lung cancer through TATDN1/miR-451/TRIM66 axis.
    Wang L, Shang X, Feng Q.
    Cancer Biol Ther; 2019 Jul 12; 20(3):261-271. PubMed ID: 30481109
    [Abstract] [Full Text] [Related]

  • 8. Long non-coding RNA MALAT1 regulates proliferation, apoptosis, migration and invasion via miR-374b-5p/SRSF7 axis in non-small cell lung cancer.
    Song J, Su ZZ, Shen QM.
    Eur Rev Med Pharmacol Sci; 2020 Feb 12; 24(4):1853-1862. PubMed ID: 32141554
    [Abstract] [Full Text] [Related]

  • 9. Long non‑coding RNA LUCAT1 contributes to cisplatin resistance by regulating the miR‑514a‑3p/ULK1 axis in human non‑small cell lung cancer.
    Shen Q, Xu Z, Xu S.
    Int J Oncol; 2020 Oct 12; 57(4):967-979. PubMed ID: 32945379
    [Abstract] [Full Text] [Related]

  • 10. MiR-488 inhibits proliferation and cisplatin sensibility in non-small-cell lung cancer (NSCLC) cells by activating the eIF3a-mediated NER signaling pathway.
    Fang C, Chen YX, Wu NY, Yin JY, Li XP, Huang HS, Zhang W, Zhou HH, Liu ZQ.
    Sci Rep; 2017 Jan 11; 7():40384. PubMed ID: 28074905
    [Abstract] [Full Text] [Related]

  • 11. Depletion of lncRNA MALAT1 inhibited sunitinib resistance through regulating miR-362-3p-mediated G3BP1 in renal cell carcinoma.
    Wang Z, Chang X, Zhu G, Gao X, Chang L.
    Cell Cycle; 2020 Aug 11; 19(16):2054-2062. PubMed ID: 32663095
    [Abstract] [Full Text] [Related]

  • 12. Long non‑coding RNA TP73‑AS1 accelerates the progression and cisplatin resistance of non‑small cell lung cancer by upregulating the expression of TRIM29 via competitively targeting microRNA‑34a‑5p.
    Luo S, Shen M, Chen H, Li W, Chen C.
    Mol Med Rep; 2020 Nov 11; 22(5):3822-3832. PubMed ID: 32901838
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Ultrasound microbubbles-mediated miR-216b affects MALAT1-miRNA axis in non-small cell lung cancer cells.
    Wang J, Mo J, Xie Y, Wang C.
    Tissue Cell; 2022 Feb 11; 74():101703. PubMed ID: 34896788
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. LncRNA MALAT1 contributes to non-small cell lung cancer progression via modulating miR-200a-3p/programmed death-ligand 1 axis.
    Wei S, Wang K, Huang X, Zhao Z, Zhao Z.
    Int J Immunopathol Pharmacol; 2019 Feb 11; 33():2058738419859699. PubMed ID: 31240979
    [Abstract] [Full Text] [Related]

  • 18. The functional status of DNA repair pathways determines the sensitization effect to cisplatin in non-small cell lung cancer cells.
    Chen P, Li J, Chen YC, Qian H, Chen YJ, Su JY, Wu M, Lan T.
    Cell Oncol (Dordr); 2016 Dec 11; 39(6):511-522. PubMed ID: 27473273
    [Abstract] [Full Text] [Related]

  • 19. Deregulation of lncRNA-AC078883.3 and microRNA-19a is involved in the development of chemoresistance to cisplatin via modulating signaling pathway of PTEN/AKT.
    Xing S, Qu Y, Li C, Huang A, Tong S, Wu C, Fan K.
    J Cell Physiol; 2019 Dec 11; 234(12):22657-22665. PubMed ID: 31111480
    [Abstract] [Full Text] [Related]

  • 20. Knockdown of lncRNA ANRIL inhibits the development of cisplatin resistance by upregulating miR‑98 in lung cancer cells.
    Wang X, Zhang G, Cheng Z, Dai L, Jia L, Jing X, Wang H, Zhang R, Liu M, Jiang T, Yang Y, Yang M.
    Oncol Rep; 2020 Sep 11; 44(3):1025-1036. PubMed ID: 32705261
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.